Udine, Italy

Maria Paternoster

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Laboratorio Chimico Internazionale S.p.a.. Active years: 2016.

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Maria Paternoster: Innovator in Pharmaceutical Processes

Introduction

Maria Paternoster is a notable inventor based in Udine, Italy. She has made significant contributions to the field of pharmaceuticals, particularly in the preparation of sevelamer, a compound used in the treatment of kidney disease. Her innovative approach has led to the development of a process that enhances the efficiency of sevelamer production.

Latest Patents

Maria holds 1 patent for her invention titled "Process for the preparation of sevelamer." This patent details a method for producing sevelamer hydrochloride and sevelamer carbonate/bicarbonate. The process is designed to yield high-quality sevelamer using conventional reactors, eliminating the need for specialized and costly equipment.

Career Highlights

Maria Paternoster is associated with Laboratorio Chimico Internazionale S.p.a., where she has applied her expertise in chemical processes. Her work has been instrumental in advancing pharmaceutical manufacturing techniques, making them more accessible and cost-effective.

Collaborations

Throughout her career, Maria has collaborated with esteemed colleagues, including Flavio Villani and Bruno De Angelis. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Maria Paternoster exemplifies the spirit of innovation in the pharmaceutical industry. Her contributions to the preparation of sevelamer highlight her commitment to improving healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…